Vical Incorporated Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting

GENEVA, Feb. 13, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today presented to the world’s leading pandemic influenza vaccine experts a summary of complete results from the company’s successful Phase 1 trial and future goals for its pandemic influenza DNA vaccine program. Larry R. Smith, Ph.D., Vical’s Vice President of Vaccine Research, presented the results and outlook at the invitation-only 5th WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials (Geneva - February 12-13).